| 產(chǎn)品編號(hào) | BIO1001SM |
| 英文名稱 | Anti-CD3 & GD2 Reference Antibody (Nivatrotamab Biosimilar) |
| 別 名 | CD3 & GD2; Nivatrotamab |
| 抗體來(lái)源 | |
| 克隆類型 | Monoclonal |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 200.96kDa |
| 性 狀 | Lyophilized |
| 亞 型 | IgG-ScFv |
| 純化方法 | Protein A |
| 緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| 保存條件 | -80°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Co-incubation of Nivatrotamab with Jurkat cells, then with the addition of hu GD2-his-293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Nivatrotamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.979 nM.
Nivatrotamab bound to hu GD2-293 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Nivatrotamab bound to hu GD2-293 cells, and the EC50 was 68.100 nM.
Nivatrotamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Nivatrotamab bound to huCD3e-jurkat cells, and the EC50 was 3.481 nM.
The purity of Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) is 100.00%, determined by SEC-HPLC.
Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The detected molecular weight of Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) is 200.83 kDa.
|
